{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:20:39Z","timestamp":1777587639550,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urolonc.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T04:51:12Z","timestamp":1765428672000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-7007","authenticated-orcid":false,"given":"Pooja","family":"Gokhale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akwasi","family":"Akosah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-4595","authenticated-orcid":false,"given":"Lorenzo","family":"Villa Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.11.010_bib0001","unstructured":"Bladder cancer. Available from: https:\/\/www.iarc.who.int\/cancer-type\/bladder-cancer\/. Accessed December 3, 2025."},{"key":"10.1016\/j.urolonc.2025.11.010_bib0002","unstructured":"NCI: surveillance, Epidemiology, and End results program: cancer stat facts, bladder cancer. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html\/. Accessed December 3, 2025."},{"issue":"19","key":"10.1016\/j.urolonc.2025.11.010_bib0003","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0004","series-title":"Bladder cancer","author":"Leslie","year":"2025"},{"issue":"8","key":"10.1016\/j.urolonc.2025.11.010_bib0005","first-page":"507","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"Bmj"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0007","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Bladder Cancer. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417. Accessed June 2025."},{"issue":"5","key":"10.1016\/j.urolonc.2025.11.010_bib0008","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.11.010_bib0009","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.010_bib0010","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of Immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.11.010_bib0012","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.eururo.2022.01.028","article-title":"Adverse events of Immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"Eur Urol"},{"issue":"10236","key":"10.1016\/j.urolonc.2025.11.010_bib0013","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.urolonc.2025.11.010_bib0014","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"lancet Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.11.010_bib0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0016","doi-asserted-by":"crossref","unstructured":"Bajorin D.F., Witjes J.A., Gschwend J.E., Schenker M., Valderrama B.P., Tomita Y., et al. Adjuvant Nivolumab versus Placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314.","DOI":"10.1056\/NEJMoa2034442"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0017","doi-asserted-by":"crossref","unstructured":"Bellmunt J., de Wit R., Vaughn D.J., Fradet Y., Lee J.L., Fong L., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","DOI":"10.1056\/NEJMoa1613683"},{"issue":"13","key":"10.1016\/j.urolonc.2025.11.010_bib0018","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"10122","key":"10.1016\/j.urolonc.2025.11.010_bib0019","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.urolonc.2025.11.010_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2023.08.012","article-title":"Pembrolizumab with or without Lenvatinib as first-line therapy for patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind trial","volume":"85","author":"Matsubara","year":"2024","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2025.11.010_bib0021","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.010_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.11.010_bib0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1078-0432.CCR-24-1728","article-title":"A phase II open-label, randomized clinical trial of Atezolizumab with or without Human recombinant IL-7 (CYT107) in advanced urothelial cancer","volume":"31","author":"Sweis","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.urolonc.2025.11.010_bib0024","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1002\/cncr.33067","article-title":"A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.11.010_bib0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.886930","article-title":"Immune related adverse events of the thyroid - a narrative review","volume":"13","author":"Muir","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0028","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/IJGM.S261433","article-title":"Thyroid dysfunctions due to immune checkpoint inhibitors: a review","volume":"13","author":"El Sabbagh","year":"2020","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103376","article-title":"Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis","volume":"163","author":"Han","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.11.010_bib0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/1759-7714.13275","article-title":"Management of immune checkpoint inhibitor-related dermatologic adverse events","volume":"11","author":"Si","year":"2020","journal-title":"Thorac Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2025.11.010_bib0031","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.651553","article-title":"Risk of pneumonitis associated with immune checkpoint inhibitors in melanoma: a systematic review and network meta-analysis","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.010_bib0033","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1759-7714.13240","article-title":"Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis","volume":"11","author":"Wang","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and management. a systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.010_bib0036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0037","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-030-02505-2_8","article-title":"Immune checkpoint inhibitors-induced Hepatitis","volume":"995","author":"Tian","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.11.010_bib0038","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14737175.2017.1336088","article-title":"Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Eltobgy","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"10.1016\/j.urolonc.2025.11.010_bib0039","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ajco.13346","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","volume":"17","author":"Zhong","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.11.010_bib0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cpm.2019.12.013","article-title":"Lack of transparency in publishing negative clinical trial results","volume":"37","author":"Snyder","year":"2020","journal-title":"Clin Podiatr Med Surg"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.010_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with Immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.urolonc.2025.11.010_bib0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.21873\/cdp.10219","article-title":"Prognostic significance of immune-related adverse events in metastatic renal cell carcinoma patients treated with immune-checkpoint-inhibitors","volume":"3","author":"Yasuda","year":"2023","journal-title":"Cancer Diagn Progn"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108555","article-title":"Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens","volume":"204","author":"Sugai","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.urolonc.2025.11.010_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102787","article-title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.urolonc.2025.11.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.urolonc.2025.11.010_bib0046","doi-asserted-by":"crossref","first-page":"12861","DOI":"10.1002\/cam4.5967","article-title":"Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors","volume":"12","author":"Looman","year":"2023","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.urolonc.2025.11.010_bib0047","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:30:24Z","timestamp":1769257824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1078143925004703"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.11.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}